BRIEF-Bristol-Myers Squibb Co - Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY

0.00

June 2 (Reuters) - Bristol-Myers Squibb Co BMY.N:

  • BRISTOL-MYERS SQUIBB CO - IZALONTAMAB BRENGITECAN SHOWS SIGNIFICANT OS AND PFS IMPROVEMENTS IN TNBC AND ESCC

  • BRISTOL-MYERS SQUIBB CO - NDA FOR IZA-BREN IN ESCC ACCEPTED BY CHINA NMPA FOR PRIORITY REVIEW

  • BRISTOL-MYERS SQUIBB: IZA-BREN SHOWED MANAGEABLE SAFETY PROFILE IN THIS HEAVILY PRE-TREATED PATIENT POPULATION, WITH NO NEW SAFETY SIGNALS OBSERVED

Source text: ID:nBw7TYxLJa

Further company coverage: BMY.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.